Russell Investments Group Ltd. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,287 shares of the company’s stock after selling 8,396 shares during the quarter. Russell Investments Group Ltd.’s holdings in IDEXX Laboratories were worth $116,372,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the business. R Squared Ltd acquired a new stake in IDEXX Laboratories during the third quarter worth approximately $562,000. Three Bridge Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $80,000. UNIVEST FINANCIAL Corp raised its holdings in IDEXX Laboratories by 3.5% in the 3rd quarter. UNIVEST FINANCIAL Corp now owns 8,358 shares of the company’s stock valued at $4,364,000 after acquiring an additional 282 shares in the last quarter. Jacobi Capital Management LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $191,000. Finally, Jefferies Financial Group Inc. lifted its position in shares of IDEXX Laboratories by 659.7% during the 3rd quarter. Jefferies Financial Group Inc. now owns 11,380 shares of the company’s stock valued at $5,943,000 after acquiring an additional 9,882 shares during the period. 87.84% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research firms have recently issued reports on IDXX. KeyCorp began coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. UBS Group upped their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Finally, The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $717.27.
View Our Latest Report on IDEXX Laboratories
IDEXX Laboratories Price Performance
NASDAQ IDXX opened at $704.23 on Monday. The business has a fifty day moving average price of $562.41 and a two-hundred day moving average price of $573.52. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.88. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The stock has a market capitalization of $55.48 billion, a PE ratio of 47.49 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the business posted $3.22 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. Equities analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.
Insider Activity at IDEXX Laboratories
In related news, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the sale, the insider directly owned 83,803 shares of the company’s stock, valued at $58,929,431.57. This trade represents a 23.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sharon E. Underberg sold 8,906 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president owned 7,169 shares in the company, valued at approximately $4,936,501.71. This represents a 55.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 41,428 shares of company stock worth $28,567,934 in the last three months. Insiders own 0.79% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Recommended Stories
- Five stocks we like better than IDEXX Laboratories
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
